HEPA - Hepion Pharmaceuticals, Inc.

0.4878
0.078   15.949%

Share volume: 84,224,176
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.07%

PREVIOUS CLOSE
CHG
CHG%
$0.41
0.08
0.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 25%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
10.86%
1 Month
574.69%
3 Months
-4.35%
6 Months
-18.02%
1 Year
-78.61%
2 Year
-96.66%
Key data
Stock price
$0.49
P/E Ratio 
N/A
DAY RANGE
$0.41 - $0.75
EPS 
-$2.54
52 WEEK RANGE
$0.02 - $2.35
52 WEEK CHANGE
-$78.13
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
5.799 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-18-2025
NEXT EARNINGS DATE
04-15-2025
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$19,426,566
AVERAGE 30 VOLUME 
$29,149,755
Company detail
CEO: Robert T. Foster
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.

Recent news
loading